The present invention relates to compounds of formula (I), pharmaceutically acceptable salts thereof, hydrates thereof, solvates thereof, prodrugs thereof and combinations thereof: wherein X represents CH or N; Y represents CH or N; R1 represents H or C1-2alkyl; R2 represents H or C1-4alkyl; R3 represents C1-6alkyl, carbocyclyl, carbocyclylC1-4alkyl, heterocyclyl or heterocyclylC1-4alkyl, wherein any of the carbocyclyl or heterocyclyl groups are optionally substituted by one or two groups selected from: halogen, C1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, nitro, cyano, -COH, -COOH, C1-6alkoxycarbonyl, C1-6alkylcarbonyl, -C(OH)R5R6 (wherein R5 and R6 independently represent H or C1-6alkyl), -(CH2)nNR3aR3b and -O(CH2)pNR3aR3b (wherein n represents 1, 2 or 3, p represents 2 or 3 and R3a and R3b independently represent H, C1-6alkyl or carbocyclylC1-4alkyl, or R3a and R3b together with the interconnecting atoms form a 5 or 6-membered ring which ring optionally contains one or two heteroatoms independently selected from the group consisting of O, S and N); R4 represents H, hydroxy, halo, C 1-6 alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, C2-6alkenyl, C1-6alkoxy, haloC1-6alkoxy, carbocyclyl or heterocyclyl, wherein the carbocyclyl or heterocyclyl group is optionally substituted by one or two groups selected from: halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, nitro and cyano; and provided that the compound is not: 7-chloro-5-phenyl-[1,2,4]triazolo[4,3-a]quinolin-4-amine; 7-chloro-1-methyl-5-phenyl[1,2,4]triazolo[4,3-a]quinolin-4-amine; or 7-chloro-5-(2-chlorophenyl)-1-methyl-{1,2,4]triazolo[4,3-a]quinolin-4-amine. Also disclosed are pharmaceutical compositions containing the compounds and to their use in medicine. The compound exhibit increased apo-A1 production and are useful in the treatment for example a disease or condition caused by raised levels of LDL-cholesterol or by inflammation.